A Study of LY3454738 in Adults With Chronic Spontaneous Urticaria

J1B-MC-FRCF -

The reason for this study is to see if the study drug LY3454738 is safe and effective as treatment for participants with hives that are caused by chronic spontaneous urticaria (CSU) and that are not controlled with H1-antihistamines.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
What the trial is testing?
Could I receive a Placebo?
Yes
Enrollment Goal
52
Trial Dates
Nov 15, 2019 - Feb 24, 2021
How long will I be in the trial?
The study will last about 39 weeks and may include up to 18 visits.
Trial Phase
II

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.